Tavo Biotherapeutics

Tavo Biotherapeutics is a biotech company developing novel therapeutics aimed at addressing significant unmet medical needs in ophthalmology, with a particular emphasis on preserving vision and improving long-term outcomes for patients with glaucoma and retinal disease. The company is advancing TAV-001, a potential disease-modifying topical therapy for glaucoma that acts as an Autonomic Nervous System Modulator — a new class of therapy designed to work with the eye's own regulatory systems by reducing intraocular pressure, improving ocular perfusion, and providing neuroprotection. TAV-001 has completed a Phase 1b clinical trial and is moving into a Phase 2 trial in the second half of 2026. TAV-002 is a bispecific antibody targeting VEGF and an upstream signaling protein for serious retinal diseases including wet and dry age-related macular degeneration and diabetes-related retinopathies. Tavo is backed by Pureos Bioventures, Polaris Partners, and Tau Capital.